Cabaletta Bio is a pre-revenue biotechnology company whose financial profile is entirely defined by its research and development pipeline, with operating losses widening to $52.0 million in Q2 2026 as R&D spending reached $44.4 million.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.28+11.8% vs -$0.32 | — vs $2M |
Q3 2026 Aug 13, 2026 | -$0.34+8.8% vs -$0.37 | — vs $2M |
Q2 2026 May 14, 2026 | -$0.39+4.9% vs -$0.41 | — vs $2M |
Q2 2026 Mar 23, 2026 | -$0.40+11.1% vs -$0.45 | — vs $833,333 |
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.
Benchmark CABA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cabaletta Bio, Inc. (CABA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $211.97M | -1.28 | — | — | -106.78% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $25.55 | $3.2B | 116.88 | 91.34% | 5.88% | 14.18% | — | |
| $38.88 | $28.09B | -105.25 | -71.57% | -3534.88% | -5.33% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — |
Cabaletta Bio, Inc. (CABA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cabaletta Bio, Inc. (CABA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 11, 2026·SEC
Jun 3, 2026·SEC
Get notified when CABA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cabaletta Bio, Inc. (CABA) stock FAQ — growth, dividends, profitability & financials explained
No. Cabaletta Bio, Inc. (CABA) reported a net loss of $189.5M over the trailing twelve months.
Cabaletta Bio, Inc. (CABA) had a return on equity (ROE) of -106.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Cabaletta Bio, Inc. (CABA) had negative free cash flow of $162.5M over the trailing twelve months.
